Can a blue dye tame Immunotherapy's dangerous side effects?

NCT ID NCT07169487

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests whether methylene blue, a dye used in medicine for other conditions, can safely treat two serious side effects of certain cancer immunotherapies: cytokine release syndrome (CRS) and immune-related neurotoxicity (ICANS). The study will enroll 18 adults with blood cancers who develop these side effects after CAR-T or bispecific antibody treatment. Participants receive methylene blue infusions for 3-5 days at different doses to find the safest and most promising dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methylene blue
What this could lead to: If it works, this could offer a new way to manage serious side effects of cancer immunotherapy, potentially making treatment safer and more tolerable.
What could go wrong: This is a very early Phase 1 trial with only 18 people, so it is too soon to know if methylene blue is safe or effective. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOKINE RELEASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytokine release syndrome hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOKINE RELEASE SYNDROME ICANS

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.